Format

Send to

Choose Destination
Ann Rheum Dis. 2016 Sep;75(9):1583-94. doi: 10.1136/annrheumdis-2016-209133. Epub 2016 Jun 23.

EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis.

Author information

1
Department of Rheumatology, Norfolk and Norwich University Hospital, Norwich, UK Norwich Medical School, University of East Anglia, Norwich, UK.
2
Norwich Medical School, University of East Anglia, Norwich, UK Department of Rheumatology, Ipswich Hospital NHS Trust, Ipswich, Suffolk, UK.
3
Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands.
4
Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
5
Assistance Publique-Hôpitaux de Paris, Department of Pulmonology, Bichat-Claude Bernard University Hospital, Paris, France.
6
Immunologie-Zentrum Zürich, Zürich, Switzerland.
7
Vaskulits-Zentrum Süd, Klinik für Innere Medizin, Rheumatologie und Immunologie, Kreiskliniken Esslingen, Kirchheim-Teck, Germany.
8
Rheumazentrum Schleswig-Holstein Mitte, Neumünster, Germany.
9
Department of Otorhinolaryngology, Head and Neck Surgery, University of Kiel, Kiel, Germany.
10
Trinity Health Kidney Centre, Tallaght Hospital, Dublin, Ireland.
11
Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford, United Kingdom.
12
Department of Internal Medicine, Hôpital Saint-Louis, Université Paris 7 René Diderot, Paris, France.
13
Division of Rheumatology and the Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
14
Vasculitis UK, West Bank House, Winster, Matlock, UK.
15
Department of Rheumatology, Norfolk and Norwich University Hospital, Norwich, UK.
16
Department of Medical and Health Sciences, Linköping University, Linköping, Sweden Department of Nephrology, Linköping University, Linköping, Sweden.
17
Department of Nephrology, 1st School of Medicine, Charles University, Prague, Czech Republic.
18
Department of Nephrology, Lund University, Skåne University Hospital, Lund and Malmö, Sweden.
19
Nephrology Unit, University Hospital of Parma, Parma, Italy.
20
Department of Ophthalmology, School of Medicine, Ankara University, Ankara, Turkey.
21
Lupus and Vasculitis Unit, Addenbrooke's Hospital, Cambridge, UK.

Abstract

In this article, the 2009 European League Against Rheumatism (EULAR) recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) have been updated. The 2009 recommendations were on the management of primary small and medium vessel vasculitis. The 2015 update has been developed by an international task force representing EULAR, the European Renal Association and the European Vasculitis Society (EUVAS). The recommendations are based upon evidence from systematic literature reviews, as well as expert opinion where appropriate. The evidence presented was discussed and summarised by the experts in the course of a consensus-finding and voting process. Levels of evidence and grades of recommendations were derived and levels of agreement (strengths of recommendations) determined. In addition to the voting by the task force members, the relevance of the recommendations was assessed by an online voting survey among members of EUVAS. Fifteen recommendations were developed, covering general aspects, such as attaining remission and the need for shared decision making between clinicians and patients. More specific items relate to starting immunosuppressive therapy in combination with glucocorticoids to induce remission, followed by a period of remission maintenance; for remission induction in life-threatening or organ-threatening AAV, cyclophosphamide and rituximab are considered to have similar efficacy; plasma exchange which is recommended, where licensed, in the setting of rapidly progressive renal failure or severe diffuse pulmonary haemorrhage. These recommendations are intended for use by healthcare professionals, doctors in specialist training, medical students, pharmaceutical industries and drug regulatory organisations.

KEYWORDS:

Corticosteroids; Cyclophosphamide; Disease Activity; Systemic vasculitis; Treatment

PMID:
27338776
DOI:
10.1136/annrheumdis-2016-209133
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center